2009 Proceedings
2008 Proceedings
2007 Program
2006 Program
4th Annual Peptide Therapeutics Symposium, November 2009
Update on development trends for peptide therapeutics by Janice M. Reichert, Ph.D., Senior Research Fellow, Tufts Center for the Study of Drug Development.
New Targets and Targeting Mechanisms for Contrast Agents and Therapeutics by Roger Tsien, Ph.D., HHMI Investigator& 2008 Nobel Laureate Chemistry, Professor Pharmacology, Chemistry and Biochemistry, UCSD.
NMR structural studies of drug receptors in membranes by Stanley Opella, Ph.D., Professor Chemistry and Biochemistry & Director Nuclear Magnetic Resonance Resource Lab, UCSD.
Peptide transduction domain mediated delivery of macromolecules; Tackling the siRNA delivery problem by Steven F. Dowdy, Ph.D., HHMI Investigator & Professor Cellular and Molecular Medicine, School of Medicine, UCSD
Peptide inhibitors of protein-protein interactions; From rational design to the clinic by Daria Mochly-Rosen, Ph.D., Professor, Chemical and Systems Biology & Senior Associate Dean for Research, School of Medicine, Stanford University.
Stapled helical peptides: A new drug modality by Noriyuki Kawahata Ph.D., Senior Principal Scientist Chemistry, Aileron Therapeutics.
Clinically validated inhibitors of intracellular protein interactions by Stephen D. Harrison, Ph.D., Senior Vice President, Research, Kai Pharmaceuticals.
Pepducins – Novel mediators of GPCR signaling by Stephen Hunt, Ph.D., Senior Vice President, Discovery Research, Ascent Therapeutics.
Linaclotide: A potential therapy for IBS-C by Mark G. Currie, Ph.D., Senior Vice President, R&D & CSO, Ironwood Pharmaceuticals Inc.
Non-Invasive systemic delivery of peptides with high bioavailability by Edward T. Maggio, Ph.D., CEO & Director, Aegis Therapeutics.
3rd Annual Peptide Therapeutics Symposium, October 2008
CovX-Body Biotherapeutics: From Concept to Applications by Joel Desharnais, Ph.D. Senior Scientist, CovX
Sustained Release of Peptides Using Microencapsulation and the Development of Long Acting Exenatide by Paul Herbert, Vice President Process Development Alkermes , Inc.
V1a Agonists in Vasodilatory Shock: From Bedside to Bench, and Back by Donald W. Landry, M.D., Ph.D., Chair, Department of Medicine, Columbia University
LAPSCOVERY Technology and Its Application to Long Acting Peptide/Protien Drugs by Gwan Sun Lee, Ph.D., Managing Research Director, Hanmi Research Center, Hanmi Pharm. Co., Ltd
Engineering Kunitz Domains Using Phage Display by Andrew E. Nixon, Ph.D., Vice President, Lead Discovery and Biochemistry, Dyax Corporation
Preformed Conjugate-Drug Affinity Complex (PC-DAC™) Technology by Martin Robitaille, Ph.D., Director, Peptide Chemistry, Conjuchem Biotechnologies, Inc.
Trends in the Clinical Development and Approval of Synthetic Peptides by Janice Reichert, Ph.D., Senior Research Fellow, Tufts Center for the Study of Drug Development
2nd Annual Peptide Therapeutics Symposium, November 2007
Building, Understanding and Leveraging a Peptide Library by Michael Hanley, Ph.D., Vice President Discovery Research, Amylin Pharmaceuticals
Application of Chemical Biotechnology to the Optimization of Protein Therapeutics by Richard Dimarchi, Ph.D., Professor, Department of Medicinal Chemistry, Indiana University
Degarelix: a novel GnRH antagonist for the treatment of prostate cancer by Per Cantor, M.D., Ph.D., Senior Vice President Clinical and Non-Clinical Development, Ferring Pharmaceuticals
KL-4 Surfactant – Form to Function by Charles Cochrane, M.D., Professor, Department of Immunology, The Scripps Research Institute
The Commercialization of Fuzeon® API by Brad DeHoff, Ph.D., Technical Manager, Roche Colorado Corp.
The Beta Cell Hormone Amylin: Discovery and Clinical Application by Andrew Young, M.D., Ph.D., Vice President , Senior Research Fellow, Amylin Pharmaceuticals
"Ynot Y2 and Y4 Peptide Agonists for Treatment of Diabetes and Obesity?” by Thue Schwartz, M.D., CSO, 7TM Pharma, University of Copenhagen
Oxyntomodulin or Products of the PYY Preproglucagon gene by Steve Bloom, M.D., Professor of Medicine, Imperial College, London
1st Annual Peptide Therapeutics Symposium, November 2006
Medicinal Chemistry of Peptide Hormones by Victor Hruby, Ph.D., Regents Professor of Chemistry, University of Arizona
GnRH: a Peptide for All Seasons by Robert Millar, Ph.D., Director, MRC Human Reproductive Sciences Unit, Ardana
Desmopressin, a Selective Antidiuretic Analog of Vasopressin by Jens Peter Norgaard, Ph.D., CSO, Urology, Ferring Pharmaceuticals
Osteoporosis, Regenerating Bone and Parathyroid Hormone by Michael Rosenblatt, Ph.D., Dean, Tufts University Medical School
History of the Development of Byetta: The Vicissitudes of Drug Development in Biotechnology by Alain D. Baron, Ph.D., Sr. Vice President, Research, Amylin Pharmaceuticals
Clinical Applications of the GLP-2 Analogue Teduglutide by Derek Chalmers, Ph.D., President & CEO, Cara Therapeutics
Current Status of Methods for Large-Scale Production of Peptides Michael Verlander, Executive Vice President, Ph.D., Polypeptide Laboratories, Inc.